<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01788605</url>
  </required_header>
  <id_info>
    <org_study_id>CBMTC-supp001</org_study_id>
    <nct_id>NCT01788605</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Prospective, Single-arm Phase 2 Trial to Evaluate Efficacy and Safety of Ramosetron in the Setting of Hematopoietic Stem Cell Transplantation for Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Catholic University of Korea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. The purpose of this study is to determine the efficacy of ramosetron for the prevention
           of emesis and the control of nausea and vomiting despite of the prophylactic antiemetic
           treatment during hematopoietic stem cell transplantation

        2. The study hypothesis is that ramosetron is effective for the prevention of emesis and
           control of emesis and/or vomiting that develop after the prophylactic antiemetic therapy
           in the setting of hematopoietic stem cell transplantation
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of ramosetron in terms of complete response (no emesis, no rescue therapy) during the conditioning regimen and within 3 or 6 days after the end of the conditioning regimen</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the efficacy of second dose of ramosetron for the treatment of breakthrough emesis</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>the number of vomiting episodes</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>grade of nausea and need for rescue therapy</measure>
    <time_frame>within 1 week after the end of conditioning regimen</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>ramosetron</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramosetron</intervention_name>
    <arm_group_label>ramosetron</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients undergoing hematopoietic stem cell transplantation conditioned with highly or
             moderately emetogenic drugs or total body irradiation (TBI) for hematologic
             malignancies

          2. aged over 18 yrs

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2

          4. patients who are able to take oral medications

          5. patients who get well-informed and sign the consent

        Exclusion Criteria:

          1. Patients complicating

               -  severe hypertension (systolic blood pressure &gt; 210 mmHg or diastolic blood
                  pressure &gt; 120 mmHg)

               -  significant heart disease such as congestive heart failure

               -  renal insufficiency (serum Cr &gt;= 3.0 mg/dL)

               -  liver disease (Aspartate aminotransferase (AST), alanine aminotransferase (ALT) &gt;
                  3 upper normal limit; alkaline phosphatase (ALP) &gt; 2 upper normal limit)

          2. Patients complicated by conditions such as gastrointestinal obstruction or active
             peptic ulcer causing emesis

          3. Patients with brain tumor, brain metastasis and epilepsy

          4. Patients with the history of extrapyramidal symptom

          5. Patients with the history of allergy to serotonin antagonists

          6. pregnant or lactating women

          7. Patients with drug abuse or psychiatric illness, or patients who are not capable of
             the normal communications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Catholic Blood &amp; Marrow Transplantation Center, Seoul St Mary's Hospital, the Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo-Kyung Kim, RN</last_name>
      <phone>82-50-7448-6371</phone>
      <email>mikaella7@naver.com</email>
    </contact>
    <contact_backup>
      <last_name>Ki-Seong Eom, MD</last_name>
      <phone>82-2-2258-6056</phone>
      <email>dreom@catholic.ac.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Jong-Wook Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2013</study_first_submitted>
  <study_first_submitted_qc>February 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2013</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Catholic University of Korea</investigator_affiliation>
    <investigator_full_name>Ki-Seong Eom, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>hematologic malignancies</keyword>
  <keyword>hematopoietic stem cell transplantation</keyword>
  <keyword>ramosetron</keyword>
  <keyword>emesis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

